An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303

Overview

This is an extended access study for participants who have completed Rufinamide Study E2080-G000-303 to continue to have access to rufinamide until it becomes commercially available in Poland or until no participants remain in the EAP.

Conditions

Interventions

Eligibility

Locations (2)

Central Contacts